How has MoonLake Immunotherapeutics's debt issuance proceeds changed year-over-year?

MoonLake Immunotherapeutics's debt issuance proceeds decreased by 66.5% year-over-year, from $73.02M to $24.47M.

What does debt issuance proceeds mean?

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

MoonLake Immunotherapeutics MLTX Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Eli LillyLLY

$0-100%

Opko HealthOPK

$8.49M+51.3%

ImmunityBio, Inc.IBRX

$61K—

Johnson & JohnsonJNJ

$0-100%

LQD

Liquidia CorporationLQDA

$0-100%

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's debt issuance proceeds?: MoonLake Immunotherapeutics (MLTX) reported debt issuance proceeds of $24.47M in Q1 2026.
How has MoonLake Immunotherapeutics's debt issuance proceeds changed year-over-year?: MoonLake Immunotherapeutics's debt issuance proceeds decreased by 66.5% year-over-year, from $73.02M to $24.47M.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.